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㩷 1) Matsumoto C., Kojima T., Ogawa K., Kamegai S., Oyama T., Shibagaki Y., Kawasaki T., 
Fujinaga H., Takahashi K., Hikiami H., Goto H., Kiga C., Koizumi K., Sakurai H., 
Muramoto H., Shimada Y., Yamamoto M., Terasawa K., Takeda S., and Saiki I.: A proteomic 
approach for the diagnosis of “Oketsu”(blood stasis), a pathophysiological concept of 
Japanese traditional (Kampo) medicine, Evid. Based Complement. Alternat. Med., 5: 
463-474, 2008. 
㩷 Abstract: 'Oketsu' is a pathophysiologic concept in Japanese traditional (Kampo) medicine, primarily 
denoting blood stasis/stagnant syndrome. Here we have explored plasma protein biomarkers and/or 
diagnostic algorithms for 'Oketsu'. Sixteen rheumatoid arthritis (RA) patients were treated with 
keishibukuryogan (KBG), a representative Kampo medicine for improving 'Oketsu'. Plasma samples were 
diagnosed as either having an 'Oketsu' (n = 19) or 'non-Oketsu' (n = 29) state according to Terasawa's 
'Oketsu' scoring system. Protein profiles were obtained by surface-enhanced laser desorption/ionization 
time-of-flight mass spectrometry (SELDI-TOF MS) and hierarchical clustering and decision tree analyses 
were performed. KBG treatment for 4 or 12 weeks decreased the 'Oketsu' scores significantly. SELDI 
protein profiles gave 266 protein peaks, whose expression was significantly different between the 'Oketsu' 
and 'non-Oketsu' states. Hierarchical clustering gave three major clusters (I, II, III). The majority (68.4%) 
of 'Oketsu' samples were clustered into one cluster as the principal component of cluster I. The remaining 
'Oketsu' profiles constituted a minor component of cluster II and were all derived from patients cured of 
the 'Oketsu' state at 12 weeks. Construction of the decision tree addressed the possibility of developing a 
diagnostic algorithm for 'Oketsu'. A reduction in measurement/pre-processing conditions (from 55 to 16) 
gave a similar outcome in the clustering and decision tree analyses. The present study suggests that the 
pathophysiologic concept of Kampo medicine 'Oketsu' has a physical basis in terms of the profile of blood 
proteins. It may be possible to establish a set of objective criteria for diagnosing 'Oketsu' using a 
combination of proteomic and bioinformatics-based classification methods. 
㩷
㩷 2) Chino A., Sekiya N., Ohno K., Hirasaki Y., Hayashi K., Kasahara Y., Kita T., Hiyama Y., 
Namiki T., Saiki I., and Terasawa K.: Clinical application of juzentaihoto for skin diseases 
and its possible mechanism. Kampo medicine, 59: 63-71, 2008 (in Japanese). 
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㩷 3) Choo M.K., Sakurai H., Kim D.H., and Saiki I.: A ginseng saponin metabolite suppresses 
tumor necrosis factor Į-promoted metastasis by suppressing nuclear factor-țB signaling in 
murine colon cancer cells. Oncol. Rep., 19: 595-600, 2008. 
㩷 Abstract: SC-514, an inhibitor of IțB kinase ȕ (IKKȕ), blocked the TNF-Į-induced activation of nuclear 
factor-țB (NF-țB) as well as the TNF-Į-promoted metastasis of murine colon adenocarcinoma cells. We 
investigated the effect of 20-O-ȕ-D-glucopyranosyl-20(S)-protopanaxadiol (M1), a main intestinal 
bacterial metabolite of ginseng, on the NF-țB-dependent metastasis. M1 was effective in suppressing the 
―64―
TNF-Į-induced activation of NF-țB, expression of matrix metalloprotease-9 (MMP-9), migration and 
invasion. The TNF-Į-evoked increase in lung and liver metastasis of colon carcinoma was also abrogated 
by treatment with M1 in vitro. These results suggest that ginseng has potential to suppress 
inflammation-related metastasis by downregulating the NF-țB signaling pathway. 
㩷 㩷
㩷 4) Ueno Y., Sakurai H., Tsunoda S., Choo M.K., Matsuo M., Koizumi K., and Saiki I.: 
Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor 
growth and metastasis in melanoma cells. Int. J. Cancer, 123: 340-347, 2008. 
㩷 Abstract: ErbB3 receptor tyrosine kinase has been shown to induce tumor progression in several types of 
cancer through heterodimerization with ErbB2. However, the role of ErbB3 and its ligand heregulin 
(HRG) in tumor metastasis remains poorly understood. In the present study, we tried to clarify their 
contributions to the metastasis of ErbB3-overexpressing B16-BL6 melanoma cells. Stimulation with HRG 
induced phosphorylation of ErbB3 and metastatic properties including MMP-9 expression, invasion, 
adhesion and experimental lung metastasis in vivo. These cellular responses were blocked by inhibiting 
the tyrosine kinase activity of EGFR with PD153035. In addition, phosphorylation of EGFR was rapidly 
induced by HRG, suggesting that EGFR is a possible heterodimeric counterpart of ErbB3. RNA 
interference demonstrated that subcutaneous tumor growth and angiogenesis was attenuated by 
inactivation of ErbB3 in cancer cells. Although experimental pulmonary metastasis was not affected by 
the knockdown of ErbB3, spontaneous metastasis was, even when primary tumors in the foot pad were 
amputated at a similar size. These results indicate that HRG-induced activation of ErbB3 via EGFR 
promotes tumor growth and metastasis of melanoma cells.  
㩷 㩷
㩷 5) Akashi T., Koizumi K., Tsuneyama K., Saiki I., Takano Y., and Fuse H.: Chemokine receptor 
CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci., 
99: 539-542, 2008. 
㩷 Abstract:  The chemokine receptor CXCR4 has been reported to be aberrantly expressed in human 
cancers and has also been shown to participate in the development of cancer metastasis. The present study 
was carried out to assess immunohistochemically the pattern of CXCR4 expression in patients with 
metastatic prostate cancer. We analyzed whether there may be an association between CXCR4 expression 
and prognosis. Fifty-two patients who received hormonal therapy were enrolled. Specimens were obtained 
from transperineal needle biopsy before treatment, and were stained with antihuman CXCR4 antibody. We 
also evaluated the pathological grade, extent of bony metastasis, clinical response to hormonal therapy, 
and patient prognosis. CXCR4 was detected in 94.2% patients. Its expression showed no association with 
pathological grade, extent of bony metastasis, or clinical response to hormonal therapy. Patients with a 
high expression of CXCR4 in tumors had poorer cancer-specific survival than those with low expression 
of CXCR4. CXCR4 expression is a useful prognostic factor for patients with metastatic prostate cancer 
treated with androgen-withdrawal therapy. 
㩷 㩷
㩷 6) Andoh T., Sugiyama K., Fujita M., Iida Y., Nojima H., Saiki I., and Kuraishi Y.: 
Pharmacological evaluation of morphine and non-opioid analgesic adjuvants in a mouse 
model of skin cancer pain. Biol. Pharm. Bull., 31: 520-522, 2008. 
㩷 Abstract:㩷Using a mouse model of advanced skin cancer which has mixed nociceptive-neuropathic pain, 
we evaluated the analgesic effects of morphine and analgesic adjuvants. Morphine hydrochloride (10--30 
mg/kg, oral) and mexiletine hydrochloride (10--30 mg/kg, intraperitoneal) dose-dependently inhibited 
thermal hyperalgesia. Baclofen (10 mg/kg, subcutaneous) suppressed thermal hyperalgesia, without 
effects at lower doses of 1 and 5 mg/kg. Ketamine hydrochloride (50 mg/kg, oral) was without effect. 
Analgesic tolerance was observed after 6th administration of morphine, and it was not developed until at 
least 7th administration of mexiletine and baclofen. This mouse model of skin cancer may be useful for the 
pharmacological evaluation of the effects of opioids and analgesic adjuvants on mixed 
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nociceptive-neuropathic pain of advanced cancer.
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㩷 7) Fujita M., Andoh T., Saiki I., and Kuraishi Y.: Involvement of endothelin and ETA 
endothelin receptor in mechanical allodynia in mice given orthotopic melanoma inoculation. 
J. Pharmacol. Sci., 106: 257-263, 2008. 
㩷 Abstract:㩷We investigated whether endothelin (ET) would be involved in skin cancer pain in mice. 
Orthotopic inoculation of B16-BL6 melanoma cells into the plantar region of the hind paw produced 
marked mechanical allodynia in C57BL/6 mice. Intraplantar injections of the ET(A)-receptor antagonist 
BQ-123 (0.3 - 3 nmol/site), but not the ET(B)-receptor antagonist BQ-788 (1 and 3 nmol/site), inhibited 
mechanical allodynia in mice with grown melanoma. In naive mice, an intraplantar injection of tumor 
extract (1 and 3 mg/site), which was prepared from the grown melanoma in the paw, produced mechanical 
allodynia, which was inhibited by BQ-123 and BQ-788 at doses of 3 and 10 nmol/site. An intraplantar 
injection of ET-1 (1 and 10 pmol/site) elicited licking behavior, which was increased in the 
melanoma-bearing hind paw. BQ-123 (3 and 10 nmol/site) inhibited licking induced by ET-1 (10 
pmol/site). The level of mRNA of ET(A), but not ET(B), receptor, was significantly increased in the dorsal 
root ganglia on the inoculated side. Cultured B16-BL6 cells contained ET, and the melanoma mass 
increased the concentration of ET as it grew bigger. These results suggest that ET-1 and ET(A) receptor are 
at least partly involved in the induction of pain induced by melanoma cell inoculation.
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㩷 8) Hashimoto I., Koizumi K., Tatematsu M., Minami T., Cho S., Takeno N., Nakashima A., 
Sakurai H., Saito S., Tsukada K., and Saiki I.: Blocking on the CXCR4/mTOR signaling 
pathway induces the anti-metastatic properties and autophagic cell death in peritoneal 
disseminated gastric cancer cells. Eur. J. Cancer, 44: 1022-1029, 2008. 
㩷 Abstract: Patients with advanced gastric carcinoma, especially peritoneal dissemination, have a poor 
prognosis even after any treatment. Chemokines are now known to play an important role in cancer 
growth and metastasis. We recently reported that the chemokine CXCL12 plays an important role in the 
development of peritoneal carcinomatosis from gastric carcinoma. In this study, we investigated signalling 
pathway involved in the peritoneal carcinomatosis induced by chemokine CXCL12. Akt was rapidly and 
strongly phosphorylated by chemokine CXCL12. CXCL12 also induced the activation of p70S6K (S6K) 
and eukaryotic initiation factor 4E binding protein 1 (4E-BP1) included in mammalian target of rapamycin 
(mTOR) pathways which are located downstream of Akt, resulting in enhancements of metastatic 
properties such as MMP production, cell migration and cell growth in peritoneal disseminated gastric 
cancer, NUGC4 cells. Furthermore, mTOR inhibitor rapamycin not only drastically inhibited migration 
and MMP production, but also induced type II programmed cell death, autophagic cell death. In the 
present study, we have shown for the first time that the mTOR pathway plays a central role in the 
development of peritoneal carcinomatosis, and blocking this pathway induces autophagic cell death in 
disseminated gastric cancer. Therefore, blocking on the CXCR4/mTOR signalling pathway may be useful 
for the future development of a more effective therapeutic strategy for gastric cancer involved in 
peritoneal dissemination. 
㩷 9) Kamiyama H., Usui T., Sakurai H., Shoji M., Hayashi Y., and Osada H.: Epoxyquinol B, a 
naturally occurring pentaketide dimmer, inhibits NF-țB signaling by crosslinking TAK1. 
Biosci. Biotech. Biochem., 72: 1894-1900, 2008. 
㩷 Abstract: Several epoxyquinoids interfere with NF-țB signaling by targeting IKKȕ or NF-țB. We report 
that epoxyquinol B (EPQB), classified as an epoxyquiniod, inhibits NF-țB signaling through inhibition of 
the TAK1 complex, a factor upstream of IKKȕ and NF-țB. cDNA microarray analysis revealed that EPQB 
decreased TNF-Į-induced expression of NF-țB target genes. EPQB covalently bound to a recombinant 
TAK1-TAB1 fusion protein in vitro, and inhibited its kinase activity. Furthermore, in vitro/in situ
treatment with EPQB resulted in a ladder-like hypershift of TAK1 protein bands. We reported recently that 
EPQB crosslinks proteins via cysteine residues by opening its two epoxides, and our current results 
suggest that EPQB inhibits NF-țB signaling by crosslinking TAK1 itself or TAK1 through other proteins.
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㩷 11) Kiga C., Sakurai H., Goto H., Hayashi K., Shimada Y., and Saiki I.: Proteomic identification 
of haptoglobin as a stroke plasma biomarker in spontaneously hypertensive stroke-prone 
rats. Life Sci., 83: 625-631, 2008. 
㩷 Abstract: AIMS: We investigated changes in the expression of plasma proteins in spontaneously 
hypertensive stroke-prone rats (SHRSP) to identify stroke biomarkers. MAIN METHODS AND KEY 
FINDINGS: The present analysis using surface-enhanced laser desorption/ionization time of flight mass 
spectrometry (SELDI-TOF-MS) demonstrated that three peaks at mass/charge ratios (m/z) of 9330, 9480 
and 9700 decreased in intensity during the development and progression of hypertensive stroke in 
SHRSPs, but not in age-matched control SHR and Wistar rats. Administration of verapamil, an L-type 
calcium channel blocker which was effective for hypertension in SHRSP rats, prevented the decrease in 
plasma protein expression. A candidate biomarker protein (m/z 9330) was identified using LC-MS/MS as 
haptoglobin (Hp). Immunoblotting with anti-Hp antibody demonstrated the decreased expression of both 
HpĮand Hpȕ chains in SHRSP. In contrast, haptoglobin mRNA expression in the liver of SHRSPs slightly 
increased as compared with control rats. SIGNIFICANCE: These findings suggest that Hp is a biomarker 
candidate for discriminating pathogenic alterations of stroke. 
㩷 12) Kiga C., Goto H., Sakurai H., Hayashi K., Hikiami H., Shimada Y., and Saiki I.: Effect of 
traditional Japanese (Kampo) medicines (orengedokuto, goreisan and shichimotsukokato) 
on the onset of stroke and expression pattern of plasma proteins in spontaneously 
stroke-prone rats. J. Trad. Med., 25: 125-132, 2008. 
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